Moderna (NASDAQ:MRNA) PT Raised to $163.00 at Oppenheimer

Moderna (NASDAQ:MRNA) had its price objective boosted by research analysts at Oppenheimer from $142.00 to $163.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 30.40% from the stock’s previous close.

MRNA has been the subject of several other research reports. HSBC reiterated a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday. Canaccord Genuity Group raised their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $129.55.

Moderna Stock Down 0.5 %

NASDAQ MRNA opened at $125.00 on Friday. The company has a current ratio of 4.03, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna has a 12 month low of $62.55 and a 12 month high of $142.79. The stock’s 50 day moving average is $105.05 and its 200 day moving average is $94.42. The stock has a market cap of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. Research analysts predict that Moderna will post -7.47 EPS for the current fiscal year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at $809,235.49. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Moderna news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares in the company, valued at $809,235.49. The disclosure for this sale can be found here. Insiders have sold 139,954 shares of company stock valued at $14,822,576 in the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Large investors have recently made changes to their positions in the business. Raymond James & Associates grew its stake in shares of Moderna by 20.3% during the 3rd quarter. Raymond James & Associates now owns 186,342 shares of the company’s stock worth $19,247,000 after purchasing an additional 31,423 shares during the period. Stratos Wealth Advisors LLC acquired a new stake in Moderna during the third quarter valued at $312,000. Mn Services Vermogensbeheer B.V. increased its holdings in Moderna by 2.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 160,200 shares of the company’s stock valued at $16,547,000 after buying an additional 4,000 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Moderna by 88.3% in the third quarter. Brown Advisory Inc. now owns 6,142 shares of the company’s stock worth $634,000 after acquiring an additional 2,880 shares during the period. Finally, Strategic Investment Advisors MI boosted its stake in shares of Moderna by 50.0% during the 3rd quarter. Strategic Investment Advisors MI now owns 6,379 shares of the company’s stock worth $659,000 after acquiring an additional 2,126 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.